Key result
Phosphodiesterase 5 inhibitors dilate the large epicardial coronary artery and selectively lower pulmonary arterial pressure in animal models, suggesting potential utility for cardiovascular diseases.
Why the study?
Do PDE 5 inhibitors improve hemodynamic parameters in animal models of cardiovascular disease?
Population
Animal models (conscious pigs, animal models of congestive heart failure or pulmonary hypertension)
Design
Review
Authors
Loading...
Supports exploration of PDE5 inhibitors for HF and PH; leaves open translation from animal models to clinical practice.
Do PDE 5 inhibitors improve hemodynamic parameters in animal models of cardiovascular disease?
Preclinical evidence suggests PDE 5 inhibitors may be a promising therapeutic avenue for heart failure, pulmonary hypertension, and angina by modulating cGMP levels in vascular smooth muscle.
Saeki et al. (1996) conducted a review in Cardiovascular diseases (heart failure, pulmonary hypertension, angina). Phosphodiesterase 5 (PDE 5) inhibitors was evaluated. Phosphodiesterase 5 inhibitors dilate the large epicardial coronary artery and selectively lower pulmonary arterial pressure in animal models, suggesting potential utility for cardiovascular diseases.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: